Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Banc of America Lowers Intermune to 'Neutral'

Banc of America downgraded Intermune (ITMN) to neutral from buy.

Analyst Michael King says shares reached his $24 target, which he feels represents fair value. He doesn't foresee any near-term catalysts to drive shares higher. He says while he believes new management has cut spending, the company could still be sold, and he sees limited upside at the current valuation.

King says while sales for lead product Actimmune are still growing, controversy remains about the drug in the clinical community. He says he would become more positive on a lower stock price or accelerating Actimmune sales growth. He'll keep his eye on prescription trends for Actimmune.

blog comments powered by Disqus